Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. With a volume of ...

However, the bank does believe that the sell-off of Lilly stock on the news (Lilly shares were down 12% yesterday, although part of that was due to earnings) is "overdone." In JPMorgan's view ...

Lilly’s tirzepatide medicines face strong competition from Novo Nordisk’s NVO GLP-drug semaglutide, which is approved as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks Consensus Estimate of $3.52 per share. Earnings rose 29% year over year.

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. Oligonucleotides work as ...

In 2025, Lilly also expects an unfavorable impact from foreign exchange rates on the top line. Sales of Trulicity are likely to have been hurt by competitive dynamics and lower realized prices in ...

Eli Lilly currently markets two GLP-1 receptor agonist medications: Tirzepatide, sold under the brand names Mounjaro and Zepbound, and Dulaglutide, sold as Trulicity. Recently, BofA’s four-star ...